Leptin and insulin act on POMC neurons to promote the browning of white fat
The pipeline continues to expand: Novo Nordisk filed an NDA for CagriSema (semaglutide + cagrilintide) in December 2025, which achieved 22.7% weight loss in the REDEFINE 1 trial, and Eli Lilly reported Phase 3 results for retatrutide , a triple GIP/GLP-1/glucagon agonist that delivered 28.7% weight loss
For example, the New Jersey Supreme Court entered an order that designated all pending and future GLP-1 gastrointestinal-injury cases as multicounty litigation (MCL) and centralized them in Bergen County for coordinated management before Judge Gregg A
Most GLP-1 users are eating far less than they realize
For more on this, see our guide to How to Prevent Ozempic Face While Using Weight Loss Injections, and how it is evaluated and treated at Perfect B in Doral
Therapeutic advances in chronic disease, 13, 20406223221108064